Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

OBJECTIVE: To compare the safety and efficacy of switching from reference adalimumab to adalimumab biosimilar CT-P17 with continuing reference adalimumab/CT-P17 in active RA. METHODS: This double-blind, phase III study randomized (1:1) subjects with active RA to receive 40 mg (100 mg/ml) CT-P17 or E...

Descripción completa

Detalles Bibliográficos
Autores principales: Furst, Daniel E, Jaworski, Janusz, Wojciechowski, Rafal, Wiland, Piotr, Dudek, Anna, Krogulec, Marek, Jeka, Slawomir, Zielinska, Agnieszka, Trefler, Jakub, Bartnicka-Maslowska, Katarzyna, Krajewska-Wlodarczyk, Magdalena, Klimiuk, Piotr A, Lee, Sang Joon, Kim, Sung Hyun, Bae, Yun Ju, Yang, Go Eun, Yoo, Jae Kyoung, Kay, Jonathan, Keystone, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996790/
https://www.ncbi.nlm.nih.gov/pubmed/34142111
http://dx.doi.org/10.1093/rheumatology/keab460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996790/
https://www.ncbi.nlm.nih.gov/pubmed/34142111
http://dx.doi.org/10.1093/rheumatology/keab460

Ejemplares similares